Moderna Stock Price – Should You Buy?

by admin

If you’re considering buying Moderna stock, you may want to look at its recent earnings report. The company procured $4.7B in revenue during the 2Q of Fiscal 2022, up from $4.3B a year prior. This significant jump was largely due to higher product sales, particularly of its COVID vaccine.

Moderna is a growing biotech that leverages mRNA technology to make drugs and vaccines. The company has the potential to be a lucrative source of revenue in the coming years as more people are vaccinated against COVID. Additionally, Moderna’s pipeline includes a variety of vaccines for different conditions and rare diseases. Furthermore, the company is well-capitalized and has the ability to acquire other companies.

Moderna is currently trading at 2.6X cash. The company’s pipeline consists of multiple therapeutics and vaccines and has $21 billion in topline revenue. With $18 billion in cash on hand, Moderna is trading for an exceptionally cheap price. If you have a healthy portfolio, it might make sense to consider buying this stock.

Moderna stock has a breakout opportunity today after Merck announced a co-development agreement. The two companies will jointly develop a personalized cancer vaccine that helps create specialized killer cells targeted at specific tumor mutations. The company will also begin testing the vaccine in combination with Merck’s Keytruda drug.

You may also like

Leave a Comment